DiscGenics Raises $14 Million for Injectable Cell Therapy

DiscGenics closed a US $14MM Series B financing. The company is pursuing dual regulatory tracks in the U.S. and Japan for its IDCT product candidate, an injectable cell therapy to treat degenerative disc disease. Funds will support this and a manufacturing ramp-up for Phase III clinical and commercial production.

The round brings DiscGenics'...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us